A triple GLP-1/GIP/glucagon receptor agonist under active clinical investigation, demonstrating exceptional efficacy in metabolic and body composition research models.
Retatrutide (LY3437943) is a first-in-class triple incretin receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors. Phase 2 clinical data published in the New England Journal of Medicine (2023) demonstrated up to 24.2% reduction in body weight over 48 weeks — substantially exceeding outcomes seen with dual agonists at equivalent timepoints.
The tri-receptor mechanism creates layered metabolic effects. GLP-1 receptor activation reduces appetite and slows gastric emptying. GIP agonism augments GLP-1 response and reduces nausea burden. Glucagon receptor activation increases resting energy expenditure and promotes hepatic lipid oxidation — adding a thermogenic dimension absent from earlier compounds in this class.
Research applications include metabolic disease modeling, obesity mechanism studies, comparative pharmacology with semaglutide and tirzepatide, and investigation of glucagon receptor physiology in the context of GLP-1 co-agonism. Currently in Phase 3 clinical development.
| Form | Lyophilized Powder |
|---|---|
| Dosage Per Vial | 5mg |
| Molecular Weight | ~4,786.4 g/mol |
| CAS Number | N/A (investigational) |
| Purity | ≥99% (HPLC verified) |
| Storage | Store at −20°C, protected from light. Reconstitute with bacteriostatic water. |
| Research Use | In vitro / laboratory research only |
Submit a research inquiry and our team will respond within one business day.
Submit Research Inquiry →